医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LUCA Science Announces Joint Research with the University of Oxford, Nuffield Department of Women’s & Reproductive Health, on the Development of Novel Therapeutics to Improve Bioenergetics for Intrauterine Growth Restriction (IUGR)

2020年09月29日 PM11:30
このエントリーをはてなブックマークに追加


 

TOKYO

LUCA Science (Tokyo, Japan), a biotechnology company pioneering a novel class of mitochondrial therapeutics, announced today that it will collaborate with the University of Oxford’s Nuffield Department of Women’s & Reproductive Health, in joint research utilising LUCA Science’s proprietary drug delivery platform technology for the treatment of IUGR.

This collaboration was instigated by Dr Yosuke Matsumiya, the UK project director for LUCA Science, who will be coordinating the research with the University of Oxford.

About the Joint Research
The placenta is a unique organ across which nutrients are transferred from mother to baby. Abnormal placental function causes significant problems in pregnancy, including IUGR.

IUGR affects over 10 million babies worldwide/year with 200,000 deaths related to IUGR and survivors (often delivered prematurely) face not only the sequelae of preterm birth but also increased long-term risks of disease (metabolic & cardiac). The largest global causes of IUGR are malnutrition and/or failure of the placenta to effectively transfer nutrition to the baby.

Currently the only treatment for IUGR is delivery irrespective of gestation. Increasing placental cellular bioenergetics and maintaining its function is a logical alternative solution. This collaboration was formed in order to realise this solution and seeks to address this by specifically delivering therapeutics to the placenta, combining unique technology developed at LUCA Science in Japan with extensive placental research experience at the University of Oxford.

Comment from Dr. Manu Vatish*1 at the University of Oxford.

“We are very excited to be working with LUCA Science to address one of the major obstacles in obstetric care. LUCA Science’s cutting-edge technology provides a unique solution to this intractable clinical problem. Use of their novel solution to deliver mitochondria to placental tissues would increase local energy supply to a starving fetus and be a major step in developing treatments for a condition affecting vast numbers of babies worldwide.”

About LUCA Science
LUCA Science is a preclinical stage biopharmaceutical company pioneering a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs. Mitochondria are the power plants in our cells that produce energy for our bodies. LUCA Science has developed a novel method to isolate proprietary functional mitochondria which can then be stored and delivered as a biopharmaceutical agent. The advanced delivery system can be applied not just for mitochondria but also other compounds that can improve bioenergetics in specific cells or tissues.

LUCA Science recently completed $9.8 million Series A financing in September.

*1: Senior Clinical Fellow at the Nuffield Department of Women’s and Reproductive Health.

LUCA Science Inc.

Name

:

LUCA Science Inc.

Headquarters

:

3-8-3, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-0023, Japan

CEO

:

Rick C. Tsai DMD, MD

Established

:

December 25th 2018

Employees

:

12

URL

:

https://luca-science.com

Business

:

Research and development of mitochondrial biopharmaceuticals

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005462/en/

CONTACT

Media Contact:

Tomoaki Shinohara, Hiromi Ishigaki

info@luca-science.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物